Clinical Trials

8 trials
RecentStart dateEnrollment
Observational × Fatigue × Genitourinary × Clear all
NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Celgene

Completed
1,149 enrolled
GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT00477919 2019-05-15

E-MOSAIC Electronic Tool to Monitor Symptoms

Swiss Cancer Institute

Completed
264 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anorexia, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Body Weight Changes, Brain Neoplasms, Breast Neoplasms, Cachexia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Depression, Esophageal Neoplasms, Fatigue, Gallbladder Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Neoplasms, Unknown Primary, Pain, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Sarcoma, Stomach Neoplasms, Gliosarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma